Elevai Labs Inc (ELAB) Actualités

CORRECTION - Elevai Labs Inc.

NEWPORT BEACH, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- In a release earlier today by Elevai Labs Inc...

Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update

Achieves Robust Financial Performance with 74% Gross Margin and Strategic Public Offering, Bolstering Resources...

Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange

NEWPORT BEACH, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the...

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity

NEWPORT BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- EL-22 is a novel myostatin asset for the potential...

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity

Preclinical results of EL-32 demonstrated statistically significant increases in grip strength, motor function...

Form DEF 14C - Other definitive information statements

Form SC TO-I - Tender offer statement by Issuer

Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock

NEWPORT BEACH, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the...

REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy...

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors